Skip to main content

Table 3 Multiple comparison test of levels of lipid parameters among treatment duration periods.

From: Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records

Treatment duration TG (nmol/L) TC (nmol/L)
  LS mean ± SE 95% CI p value LS mean ± SE 95% CI p value
Baseline 1.51 ± 0.05 1.42/1.61 reference 5.30 ± 0.04 5.21/5.39 reference
0~3M 1.52 ± 0.07 1.39/1.65 1 5.24 ± 0.05 5.14/5.35 0.5876
3~6M 1.53 ± 0.07 1.39/1.67 0.9984 5.30 ± 0.06 5.19/5.42 1
6~9M 1.61 ± 0.08 1.45/1.77 0.6205 5.26 ± 0.06 5.13/5.39 0.9223
9~12M 1.54 ± 0.08 1.36/1.72 0.9963 5.34 ± 0.07 5.20/5.48 0.9717
Treatment duration HDL-C (nmol/L) LDL-C (nmol/L)
  LS mean ± SE 95% CI p value LS mean ± SE 95% CI p value
Baseline 1.47 ± 0.02 1.42/1.52 reference 3.12 ± 0.05 3.02/3.21 reference
0~3M 1.45 ± 0.03 1.40/1.51 0.858 3.10 ± 0.05 2.99/3.21 0.9917
3~6M 1.45 ± 0.03 1.40/1.51 0.8875 3.05 ± 0.06 2.93/3.16 0.5653
6~9M 1.40 ± 0.03 1.34/1.46 0.0218* 3.11 ± 0.06 2.98/3.23 0.9999
9~12M 1.41 ± 0.03 1.34/1.47 0.1247 3.08 ± 0.07 2.95/3.22 0.9778
  1. TG: triglyceride, TC: total cholesterol, HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, LS mean: least squares mean, SE: standard error, CI: confidence interval, p value: p value of treatment duration (compared with baseline, multiple-comparison test: Dunnett-Hsu post-hoc analysis), *: p < 0.05.